- Home
- HUMAW vs IDYA Comparison
HUMAW vs IDYA Comparison
Compare HUMAW & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUMAW
- IDYA
- Stock Information
- Founded
- HUMAW N/A
- IDYA 2015
- Country
- HUMAW United States
- IDYA United States
- Employees
- HUMAW 185
- IDYA N/A
- Industry
- HUMAW Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- HUMAW Health Care
- IDYA Health Care
- Exchange
- HUMAW Nasdaq
- IDYA Nasdaq
- Market Cap
- HUMAW N/A
- IDYA 2.2B
- IPO Year
- HUMAW 2020
- IDYA 2019
- Fundamental
- Price
- HUMAW $1.74
- IDYA $26.23
- Analyst Decision
- HUMAW
- IDYA Strong Buy
- Analyst Count
- HUMAW 0
- IDYA 12
- Target Price
- HUMAW N/A
- IDYA $53.67
- AVG Volume (30 Days)
- HUMAW N/A
- IDYA 1.0M
- Earning Date
- HUMAW N/A
- IDYA 11-04-2024
- Dividend Yield
- HUMAW N/A
- IDYA N/A
- EPS Growth
- HUMAW N/A
- IDYA N/A
- EPS
- HUMAW N/A
- IDYA N/A
- Revenue
- HUMAW N/A
- IDYA $3,922,000.00
- Revenue This Year
- HUMAW N/A
- IDYA N/A
- Revenue Next Year
- HUMAW N/A
- IDYA $251.89
- P/E Ratio
- HUMAW N/A
- IDYA N/A
- Revenue Growth
- HUMAW N/A
- IDYA N/A
- 52 Week Low
- HUMAW N/A
- IDYA $24.48
- 52 Week High
- HUMAW N/A
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- HUMAW N/A
- IDYA 37.58
- Support Level
- HUMAW N/A
- IDYA $24.48
- Resistance Level
- HUMAW N/A
- IDYA $27.15
- Average True Range (ATR)
- HUMAW 0.00
- IDYA 1.34
- MACD
- HUMAW 0.00
- IDYA -0.11
- Stochastic Oscillator
- HUMAW 0.00
- IDYA 7.90
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.